The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Technologies to address antimicrobial resistance
Open accessAbstract
Bacterial infections have been traditionally controlled by antibiotics and vaccines, and these approaches have greatly improved health and longevity. However, multiple stakeholders are declaring that the lack of new interventions is putting our ability to prevent and treat bacterial infections at risk. Vaccine and antibiotic approaches still have the potential to address this threat. Innovative vaccine technologies, such as reverse vaccinology, novel adjuvants, and rationally designed bacterial outer membrane vesicles, together with progress in polysaccharide conjugation and antigen design, have the potential to boost the development of vaccines targeting several classes of multidrug-resistant bacteria. Furthermore, new approaches to deliver small-molecule antibacterials into bacteria, such as hijacking active uptake pathways and potentiator approaches, along with a focus on alternative modalities, such as targeting host factors, blocking bacterial virulence factors, monoclonal antibodies, and microbiome interventions, all have potential. Both vaccines and antibacterial approaches are needed to tackle the global challenge of antimicrobial resistance (AMR), and both areas have the underpinning science to address this need. However, a concerted research agenda and rethinking of the value society puts on interventions that save lives, by preventing or treating life-threatening bacterial infections, are needed to bring these ideas to fruition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Self-citationStructure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Parikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31921-3 · Cited by 275
McElhaney, J. E., Beran, J., Devaster, J.-M., Esen, M., Launay, O., Leroux-Roels, G., Ruiz-Palacios, G. M., van Essen, G. A., Caplanusi, A., Claeys, C., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70046-x · Cited by 164
Cited by
Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence
Christaki, E., Marcou, M., & Tofarides, A. (2020) · Journal of Molecular Evolution · doi:10.1007/s00239-019-09914-3 · Cited by 780
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
An Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms
Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114
Metadata
- Authors
- Baker, S. J., Payne, D. J., Rappuoli, R., & De Gregorio, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-12-17
- Volume
- 115
- Issue
- 51
- Pages
- 12887-12895
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2906672401
- Cited by
- 215
- References
- 5
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Technologies to address antimicrobial resistance. https://app.cochat.ai/papers/10.1073/pnas.1717160115
- The paper
- Baker, S. J., Payne, D. J., Rappuoli, R., & De Gregorio, E. (2018). Technologies to address antimicrobial resistance. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1717160115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.